The antiphospholipid syndrome

New England Journal of Medicine

Volumn 346, Issue 10, 2002, Pages 752-763

  Levine, Jerrold S ^a   Branch, Ware ^a   Rauch, Joyce ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; GLUCOCORTICOID; HEPARIN; HYDROXYCHLOROQUINE; PHOSPHOLIPID ANTIBODY; PREDNISONE; WARFARIN;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE PREDISPOSITION; EPIDEMIOLOGICAL DATA; MYELOPROLIFERATIVE DISORDER; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; TREATMENT PLANNING;

ABORTION, HABITUAL; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION TESTS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; RISK FACTORS; THROMBOSIS;

EID: 0037035113     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra002974     Document Type: Review

References (96)

1. The anticardiolipin syndrome
2. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: A prospective analysis of 500 consecutive patients
3. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop
4. Immunology and clinical importance of antiphospholipid antibodies
5. Anti-phosphatidylethanolamine (aPE) antibodies: A survey
6. Immunology of the antiphospholipid antibody syndrome
7. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: An explanation for their pathogenic mechanism?
8. Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome?
9. Criteria for the diagnosis of lupus anticoagulants: An update
10. Eine serodiagnostiche Reaktion bei Syphilis
11. A new serologically active phospholipid from beef heart
12. Systemic lupus erythematosus preceded by false-positive serologic tests for syphilis: Presentation of five cases
13. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus
14. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
15. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H)
16. A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection
17. Measurement of anti-phospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen
18. Lupus anticoagulant
19. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies
20. Association of anti-β2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus
21. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin
22. β2-Glycoprotein-I (apolipoprotein H) interactions with phospholipid Vesicles
23. Specificity and clinical relevance of lupus anticoagulant
24. Antiphospholipid anti-bodies and the protein C pathway
25. Overview on anticardiolipin ELISA standardization
26. The antiphospholipid/cofactor syndromes: A primary variant with antibodies to β2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays
27. Which are the best biological markers of the antiphospholipid syndrome?
28. Endothelial activation by aPL: A potential pathogenetic mechanism for the clinical manifestations of the syndrome
29. β2-Glycoprotein I as a 'cofactor' for anti-phospholipid reactivity with endothelial cells
30. Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: A unifying 'membrane stress syndrome' hypothesis
31. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus
32. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein
33. Beta2-glycoprotein I
34. Tissue factor pathway and the antiphospholipid syndrome
35. Pregnancy loss in the antiphospholipid-antibody syndrome - A possible thrombogenic mechanism
36. The pathogenesis of the antiphospholipid syndrome: A hypothesis based on parallelisms with heparin-induced thrombocytopenia
37. Antiphospholipid syndrome and heparin-induced thrombocytopenia: Update on similarities and differences
38. β2-Glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: Differences with lupus anticoagulants
39. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a β2 -glycoprotein I-dependent manner
40. Induction of anti-phospholipid autoantibodies by Β2-glycoprotein I bound to apoptotic thymocytes
41. Primary antiphospholipid syndrome
42. The "primary" antiphospholipid syndrome: Major clinical and serological features
43. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus
44. Comparison of the primary and secondary antiphospholipid syndrome: A European multicenter study of 114 patients
45. Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome
46. Pathology of the antiphospholipid syndrome
47. Exclusion criteria for primary antiphospholipid syndrome
48. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases
49. Sneddon's syndrome with anticardiolipin antibodies - Complications and treatment
50. Antiphospholipid antibodies and syndromes
51. Epidemiology of the antiphospholipid antibody syndrome
52. Systemic lupus erythematosus: Clinical and immunologic patterns of disease expression in a cohort of 1,000 patients
53. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: Prevalence and clinical significance
54. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis
55. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men
56. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies
57. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the Italian Registry
58. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy
59. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus - A meta-analysis
60. The management of thrombosis in the antiphospholipid-antibody syndrome
61. Thrombosis and antithrombotic therapy
62. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four cases
63. The intrarenal vascular lesions associated with primary antiphosphohpid syndrome
64. Renal involvement in the anti-phospholipid syndrome
65. Thrombosis in systemic lupus erythematosus: Relation to the presence of circulating anticoagulants
66. Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure
67. Insidious loss of renal function in patients with anticardiolipin antibodies and absence of overt nephritis
68. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus
69. Antiphospholipid antibodies and fetal death
70. Outcome of treated pregnancies in women with antiphospholipid syndrome: An update of the Utah experience
71. A study of sixty pregnancies in patients with the antiphospholipid syndrome
72. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone
73. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
74. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial
75. An informative protocol for the investigation of recurrent miscarriage: Preliminary experience of 500 consecutive cases
76. Antiphospholipid antibody panels and recurrent pregnancy loss: Prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies
77. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome
78. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant
79. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I
80. Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low-dose heparin treatment
81. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of anti-phospholipid syndrome during pregnancy
82. Can you manage antiphospholipid syndrome during pregnancy?
83. Management of recurrent pregnancy loss
84. Use of antithrombotic agents during pregnancy
85. Catastrophic antiphospholipid syndrome: Clinical and laboratory features of 50 patients
86. Thrombotic storm: When thrombosis begets thrombosis
87. High thrombosis rate after fetal loss in antiphospholipid syndrome: Effective prophylaxis with aspirin
88. Hydroxychioroquine use in the Baltimore Lupus Cohort: Effects on lipids, glucose and thrombosis
89. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients
90. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment
91. Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation
92. Hemorrhagic complications of long-term anticoagulant therapy in seven patients with systemic lupus erythematosus and antiphospholipid syndrome
93. The effects of low-intensity warfarin on coagulation activation in patients with antiphospholipid antibodies and systemic lupus erythematosus
94. Antiphospholipid antibodies and venous thromboembolism
95. Anticardiolipin antibodies and recurrent thromboembolism
96. Monitoring warfarin therapy in patients with lupus anticoagulants